Determination of individual organ masses for (90)Y-anti-CD66 radioimmunotherapy: influence on therapy planning.
Z Med Phys
; 21(4): 305-9, 2011 Dec.
Article
en En
| MEDLINE
| ID: mdl-21719265
Dosimetry is important in the development of radioactive pharmaceuticals, especially for optimizing radionuclide therapy with respect to risk-benefit analysis. To calculate the applied absorbed doses in the target and risk organs standard phantom masses are frequently used. However, deviations to the true organ mass can lead to suboptimal decisions in dose finding studies. To estimate the magnitude of deviations introduced when using standard phantom masses instead of individual organ masses, we investigated 10 patients treated with radioimmunotherapy using (90)Y labelled anti-CD66 antibody. The use of standard phantom masses instead of individually measured organ masses results in mean deviations for liver, spleen and kidneys of 2% (Min. -22%, Max. 34%), -3% (Min. -34, Max. 100%) und -8% (Min. -37, Max. 38%), respectively. For the administered therapeutic activity differences of -16% (Min. -45%, Max. 4%) were observed depending on the used organ mass. These results demonstrate that using standard phantom masses for dosimetry before radionuclide therapy is not adequate.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Radioisótopos de Itrio
/
Simulación por Computador
/
Planificación de la Radioterapia Asistida por Computador
/
Distribución Tisular
/
Antígenos CD
/
Moléculas de Adhesión Celular
/
Técnicas Inmunológicas
/
Radioinmunoterapia
/
Anticuerpos Monoclonales
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Z Med Phys
Asunto de la revista:
RADIOTERAPIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Alemania
Pais de publicación:
Alemania